KRAS G12C Mutant Non–Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer Registry-Reference-Cited by-同舟云学术

KRAS G12C Mutant Non–Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer Registry

Published:2023-09 Issue:6 Volume:24 Page:507-518
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Isaksson Johan^ORCID,Berglund Anders,Louie Karly,Willén Linda,Hamidian Arash,Edsjö Anders,Enlund Fredrik,Planck Maria,Vikström Anders,Johansson Mikael,Hallqvist Andreas,Wagenius Gunnar,Botling Johan^ORCID

Funder

Swedish Cancer Society

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference50 articles.

1. Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update;Hanna;J Clin Oncol,2020

2. Therapy for Stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update;Hanna;J Clin Oncol,2021

3. Comprehensive molecular profiling of lung adenocarcinoma;Nature,2014

4. Comprehensive genomic characterization of squamous cell lung cancers;Nature,2012

5. Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer;Lee;BMC Cancer,2012

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment patterns and outcomes in KRAS‐positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study;Lung Cancer;2024-08

2. Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis;BMC Cancer;2024-07-15

3. Accurate Early Detection and EGFR Mutation Status Prediction of Lung Cancer Using Plasma cfDNA Coverage Patterns: A Proof-of-Concept Study;Biomolecules;2024-06-17

4. Assessing the prognostic value of KRAS mutation combined with tumor size in stage I-II non-small cell lung cancer: a retrospective analysis;Frontiers in Oncology;2024-05-31

5. Real-World Evidence Study of Patients with KRAS-Mutated NSCLC in Finland;Current Oncology;2024-05-11